BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17578455)

  • 1. Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation.
    Aisa Y; Mori T; Nakazato T; Shimizu T; Yamazaki R; Ikeda Y; Okamoto S
    Transpl Int; 2007 Sep; 20(9):761-70. PubMed ID: 17578455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.
    Kim DH; Popradi G; Xu W; Gupta V; Kuruvilla J; Wright J; Messner HA; Lipton JH
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):471-82. PubMed ID: 19285635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eosinophilia predicts better overall survival after acute graft-versus-host-disease.
    Imahashi N; Miyamura K; Seto A; Watanabe K; Yanagisawa M; Nishiwaki S; Shinba M; Yasuda T; Kuwatsuka Y; Terakura S; Kodera Y
    Bone Marrow Transplant; 2010 Feb; 45(2):371-7. PubMed ID: 19525984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
    Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of eosinophilia after stem cell transplantation as a possible prognostic marker for favorable outcome.
    Sato T; Kobayashi R; Nakajima M; Iguchi A; Ariga T
    Bone Marrow Transplant; 2005 Dec; 36(11):985-91. PubMed ID: 16184178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective review of the outcome after second or subsequent allogeneic transplantation.
    Kedmi M; Resnick IB; Dray L; Aker M; Samuel S; Gesundheit B; Slavin S; Or R; Shapira MY
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):483-9. PubMed ID: 19285636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
    Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
    Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retrospective analysis of posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation].
    Aisa Y; Mori T; Shimizu T; Tsukada Y; Kato J; Suzuki S; Suzuki N; Ikeda Y; Okamoto S
    Rinsho Ketsueki; 2009 Jan; 50(1):9-15. PubMed ID: 19225223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.
    Min CK; Kim SY; Lee MJ; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim CC; Cho CS
    Bone Marrow Transplant; 2006 Jul; 38(2):149-56. PubMed ID: 16751784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.
    Jagasia M; Giglia J; Chinratanalab W; Dixon S; Chen H; Frangoul H; Engelhardt B; Goodman S; Greer J; Kassim A; Morgan D; Ruffner K; Schuening F
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1207-15. PubMed ID: 17889358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation.
    Ahmad I; Labbé AC; Chagnon M; Busque L; Cohen S; Kiss T; Lachance S; Roy DC; Sauvageau G; Roy J
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1673-8. PubMed ID: 21601640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD.
    Rajasekar R; Mathews V; Lakshmi KM; Sellathamby S; George B; Viswabandya A; Daniel D; Chandy M; Srivastava A
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):344-50. PubMed ID: 18275901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.